创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction to the Features of the Inoculation Platform for Hematology Tumor Modeling System

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-07 14:05
  • Views:

(Summary description)In the field of cancer research, animal models are indispensable tools that provide researchers with experimental environments that simulate human disease processes. As a leader in this field, the hematological tumor model system inoculation platform of InnoModels Biotechnology, with its unique features and advantages, opens up a new path for hematological tumor research

InnoModels: Introduction to the Features of the Inoculation Platform for Hematology Tumor Modeling System

(Summary description)In the field of cancer research, animal models are indispensable tools that provide researchers with experimental environments that simulate human disease processes. As a leader in this field, the hematological tumor model system inoculation platform of InnoModels Biotechnology, with its unique features and advantages, opens up a new path for hematological tumor research

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-07 14:05
  • Views:
Information

In the field of cancer research, animal models are indispensable tools that provide researchers with experimental environments that simulate human disease processes. As a leader in this field, the hematological tumor model system inoculation platform of InnoModels Biotechnology, with its unique features and advantages, opens up a new path for hematological tumor research.
Highly simulated human environment
The inoculation platform of InnoModels Blood Tumor Model System focuses on simulating the tumor growth environment in the human body. Through advanced bioengineering technology, the platform is able to accurately simulate the blood environment, immune system, and the growth and spreading process of tumor cells in the human body. This makes the research results more informative and practical.
Multiple Inoculation Options
The platform provides a variety of inoculation methods for blood tumor models, including intravenous injection, bone marrow transplantation, etc., to meet different research needs. Researchers can choose the most suitable inoculation method according to the experimental purpose and tumor type, so as to more accurately simulate the pathogenesis of human diseases.
Easy to operate and highly efficient
The inoculation platform of InnoModels Blood Tumor Model System focuses on simplicity and efficiency in operation. The platform adopts advanced automated equipment and intelligent management system, which makes the experimental operation easier and faster, and at the same time improves the experimental efficiency and accuracy.
Strict Quality Control
In the process of blood tumor model preparation, the platform implements strict quality control measures. From cell culture, model construction to experimental inoculation, each step is carefully designed and strictly monitored to ensure the stability and reliability of the model.

 


Wide range of applications
The platform is not only suitable for basic research on hematological tumors, but can also be applied to drug screening and evaluation of therapeutic effects. Researchers can use the platform to conduct rapid and accurate evaluation of new anticancer drugs, which provides a strong experimental basis for the clinic.
Powerful Technical Support
Behind the inoculation platform of InnoModels' blood tumor modeling system is a professional technical team with rich experimental experience and profound professional knowledge, which can provide researchers with all-round technical support and guidance.
Environmental Protection and Safety
While pursuing scientific breakthroughs, the platform also emphasizes environmental protection and safety. The platform adopts environmentally friendly experimental materials and technical means to reduce the impact of the experimental process on the environment. At the same time, the platform also strengthens the treatment and management of experimental waste to ensure the safety of the experimental process.
In conclusion, with its highly simulated human environment, multiple inoculation options, easy operation, strict quality control, wide range of applications, strong technical support, as well as environmental protection and safety, the inoculation platform of InnoModels Biotechnology Hematology Tumor Modeling System provides powerful support for hematology tumor research. It is believed that with the continuous development and improvement of the technology, the platform will play a greater role in the field of cancer research.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司